MX2011010514A - Composiciones de capsulas biodisponibles de compuesto amorfo alfa-(n-sulfonamido)acetamida. - Google Patents
Composiciones de capsulas biodisponibles de compuesto amorfo alfa-(n-sulfonamido)acetamida.Info
- Publication number
- MX2011010514A MX2011010514A MX2011010514A MX2011010514A MX2011010514A MX 2011010514 A MX2011010514 A MX 2011010514A MX 2011010514 A MX2011010514 A MX 2011010514A MX 2011010514 A MX2011010514 A MX 2011010514A MX 2011010514 A MX2011010514 A MX 2011010514A
- Authority
- MX
- Mexico
- Prior art keywords
- sulfonamido
- capsule compositions
- acetamide compound
- amorphous alpha
- bioavailable
- Prior art date
Links
- 239000007963 capsule composition Substances 0.000 title abstract 2
- -1 acetamide compound Chemical class 0.000 title 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 title 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 229920001223 polyethylene glycol Polymers 0.000 abstract 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 2
- XEAOPVUAMONVLA-QGZVFWFLSA-N Avagacestat Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](CCC(F)(F)F)C(=O)N)CC(C(=C1)F)=CC=C1C=1N=CON=1 XEAOPVUAMONVLA-QGZVFWFLSA-N 0.000 abstract 1
- 229930003427 Vitamin E Natural products 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229920001531 copovidone Polymers 0.000 abstract 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 1
- 229920002689 polyvinyl acetate Polymers 0.000 abstract 1
- 239000011118 polyvinyl acetate Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- 229940046009 vitamin E Drugs 0.000 abstract 1
- 235000019165 vitamin E Nutrition 0.000 abstract 1
- 239000011709 vitamin E Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16906109P | 2009-04-14 | 2009-04-14 | |
| PCT/US2010/030862 WO2010120755A1 (en) | 2009-04-14 | 2010-04-13 | Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011010514A true MX2011010514A (es) | 2011-11-29 |
Family
ID=42235859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011010514A MX2011010514A (es) | 2009-04-14 | 2010-04-13 | Composiciones de capsulas biodisponibles de compuesto amorfo alfa-(n-sulfonamido)acetamida. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8252821B2 (enExample) |
| EP (1) | EP2419090B1 (enExample) |
| JP (1) | JP2012524092A (enExample) |
| KR (1) | KR20120022766A (enExample) |
| CN (1) | CN102395361A (enExample) |
| AR (1) | AR076305A1 (enExample) |
| AU (1) | AU2010236602A1 (enExample) |
| BR (1) | BRPI1015483A2 (enExample) |
| CA (1) | CA2758847A1 (enExample) |
| EA (1) | EA201101286A1 (enExample) |
| MX (1) | MX2011010514A (enExample) |
| NZ (1) | NZ595335A (enExample) |
| TW (1) | TW201041609A (enExample) |
| WO (1) | WO2010120755A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ533603A (en) | 2001-12-20 | 2007-02-23 | Bristol Myers Squibb Co | Alpha-(N-sulphonamido)acetamide derivatives as beta-amyloid inhibitors used for treating Alzheimer's Disease and Down's syndrome |
| US8044077B2 (en) | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
| US7977362B2 (en) | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
| EP2485416A4 (en) | 2009-10-02 | 2017-04-05 | LG Electronics Inc. | Transmission method and device for a downlink reference signal |
| NZ613167A (en) * | 2010-12-16 | 2015-09-25 | Univ Texas | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds |
| US9364433B2 (en) | 2011-04-28 | 2016-06-14 | Borje S. Andersson | Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
| US20130302414A1 (en) * | 2012-05-07 | 2013-11-14 | Bristol-Myers Squibb Company | Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| WO2020169738A1 (en) * | 2019-02-22 | 2020-08-27 | Janssen Pharmaceutica Nv | Pharmaceutical formulations |
| BR112021019799A2 (pt) | 2019-04-11 | 2021-12-07 | Janssen Pharmaceutica Nv | Derivados contendo anéis de piridina como inibidores de malt1 |
| JP2023538099A (ja) * | 2020-08-21 | 2023-09-06 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤と、ポリエチレングリコールの脂肪酸との混合物と、を含む、医薬製剤 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5274094A (en) | 1990-08-15 | 1993-12-28 | British Bio-Technology Limited | Production of heterobicyclic containing benzene sulfonamides |
| GB9202791D0 (en) | 1992-02-11 | 1992-03-25 | British Bio Technology | Compounds |
| NZ321293A (en) | 1995-11-17 | 2001-04-27 | Warner Lambert Co | Sulfonamide inhibitors of matrix metalloproteinases |
| CZ16899A3 (cs) | 1996-07-22 | 1999-08-11 | Monsanto Company | Thiolsulfonamidové inhibitory metaloproteázy |
| CA2264718C (en) * | 1996-09-01 | 2006-05-30 | Pharmos Corporation | Solid coprecipitates for enhanced bioavailability of lipophilic substances |
| JPH11343279A (ja) | 1998-03-16 | 1999-12-14 | Shionogi & Co Ltd | スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤 |
| US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
| JP2002535386A (ja) | 1999-01-27 | 2002-10-22 | アメリカン・サイアナミド・カンパニー | アセチレンスルホンアミドチオールｔａｃｅインヒビター |
| NZ514453A (en) | 1999-02-26 | 2003-04-29 | Merck & Co Inc | Novel sulfonamide compounds and uses thereof |
| DE60233150D1 (de) * | 2001-10-19 | 2009-09-10 | Isotechnika Inc | Neue cyclosporin-analoge mikroemulsionsvorkonzentrate |
| NZ533603A (en) | 2001-12-20 | 2007-02-23 | Bristol Myers Squibb Co | Alpha-(N-sulphonamido)acetamide derivatives as beta-amyloid inhibitors used for treating Alzheimer's Disease and Down's syndrome |
| RU2342374C2 (ru) | 2003-03-31 | 2008-12-27 | Уайт | Фтор- и трифторалкилсодержащие гетероциклические сульфонамидные ингибиторы образования бета-амилоида и их производные |
| RU2364587C2 (ru) | 2003-10-29 | 2009-08-20 | Элан Фармасьютикалз, Инк. | N-замещенные бензолсульфонамиды |
| US7163942B2 (en) | 2004-04-01 | 2007-01-16 | Pfizer Inc. | Sulfonamide compounds for the treatment of neurodegenerative disorders |
| EP1744731A1 (en) * | 2004-04-28 | 2007-01-24 | Procarrier, Inc. | Oral formulation for delivery of poorly absorbed drugs |
| JP4845883B2 (ja) | 2004-07-13 | 2011-12-28 | エフ．ホフマン−ラ ロシュ アーゲー | スルホンアミド誘導体 |
| US7144894B2 (en) | 2004-09-23 | 2006-12-05 | Bristol-Myers Squibb Company | Sulfonamide bicyclic compounds |
| JP2008523146A (ja) * | 2004-12-14 | 2008-07-03 | ワイス | 神経変性障害の処置および予防のための５−ｈｔ６アゴニストの使用 |
| TW200732295A (en) | 2006-02-17 | 2007-09-01 | Wyeth Corp | Selective N-sulfonylation of 2-amino trifluoroalkyl substituted alcohols |
| PE20080169A1 (es) | 2006-02-17 | 2008-04-11 | Wyeth Corp | Metodo para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios |
| WO2007103683A2 (en) * | 2006-03-01 | 2007-09-13 | Roskamp Research Llc | Compounds for inhibiting beta-amyloid production |
| US8633179B2 (en) | 2007-03-13 | 2014-01-21 | The Trustees Of Columbia University In The City Of New York | Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids |
| WO2009005688A2 (en) | 2007-06-29 | 2009-01-08 | Trustees Of Columbia University In The City Of New York | Activating mutations in notch-1 |
| US8084477B2 (en) | 2007-10-31 | 2011-12-27 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| WO2009137657A1 (en) | 2008-05-08 | 2009-11-12 | Bristol-Myers Squibb Company | 2-aryl glycinamide derivatives |
| KR20110133046A (ko) | 2009-03-19 | 2011-12-09 | 브리스톨-마이어스 스큅 컴퍼니 | 베타 아밀로이드 펩티드 생성의 억제제로서의 신규 알파-(ｎ-술폰아미도)아세트아미드 화합물 |
| US8044077B2 (en) | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
| US7977362B2 (en) | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
| US20110071199A1 (en) | 2009-03-20 | 2011-03-24 | Bristol-Myers Squibb Company | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease |
| TW201043269A (en) | 2009-04-14 | 2010-12-16 | Bristol Myers Squibb Co | Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
-
2010
- 2010-04-12 US US12/758,385 patent/US8252821B2/en not_active Expired - Fee Related
- 2010-04-13 BR BRPI1015483A patent/BRPI1015483A2/pt not_active IP Right Cessation
- 2010-04-13 CN CN2010800164919A patent/CN102395361A/zh active Pending
- 2010-04-13 EA EA201101286A patent/EA201101286A1/ru unknown
- 2010-04-13 MX MX2011010514A patent/MX2011010514A/es active IP Right Grant
- 2010-04-13 EP EP10714418A patent/EP2419090B1/en not_active Not-in-force
- 2010-04-13 JP JP2012506123A patent/JP2012524092A/ja active Pending
- 2010-04-13 KR KR1020117024036A patent/KR20120022766A/ko not_active Withdrawn
- 2010-04-13 AU AU2010236602A patent/AU2010236602A1/en not_active Abandoned
- 2010-04-13 CA CA2758847A patent/CA2758847A1/en not_active Abandoned
- 2010-04-13 NZ NZ595335A patent/NZ595335A/xx not_active IP Right Cessation
- 2010-04-13 WO PCT/US2010/030862 patent/WO2010120755A1/en not_active Ceased
- 2010-04-14 AR ARP100101257A patent/AR076305A1/es not_active Application Discontinuation
- 2010-04-14 TW TW099111671A patent/TW201041609A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20100260837A1 (en) | 2010-10-14 |
| TW201041609A (en) | 2010-12-01 |
| BRPI1015483A2 (pt) | 2016-04-26 |
| JP2012524092A (ja) | 2012-10-11 |
| CN102395361A (zh) | 2012-03-28 |
| AR076305A1 (es) | 2011-06-01 |
| WO2010120755A1 (en) | 2010-10-21 |
| NZ595335A (en) | 2013-03-28 |
| CA2758847A1 (en) | 2010-10-21 |
| AU2010236602A1 (en) | 2011-10-13 |
| EP2419090A1 (en) | 2012-02-22 |
| EA201101286A1 (ru) | 2012-04-30 |
| US8252821B2 (en) | 2012-08-28 |
| EP2419090B1 (en) | 2013-02-13 |
| KR20120022766A (ko) | 2012-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011010514A (es) | Composiciones de capsulas biodisponibles de compuesto amorfo alfa-(n-sulfonamido)acetamida. | |
| WO2009072007A3 (en) | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof | |
| EA200901319A1 (ru) | Композиции для назального введения | |
| WO2009043049A3 (en) | Pharmaceutical formulations | |
| ZA200705750B (en) | Compositions and methods for stabilizing active pharmaceutical ingredients | |
| PL1940249T3 (pl) | Nowe formulacje rozpuszczalnych w tłuszczach składników aktywnych o wysokiej biodostępności | |
| EA201390783A1 (ru) | Биоразлагаемые композиции для доставки лекарственных средств | |
| TW200744665A (en) | Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof | |
| MX2009007742A (es) | Formulaciones farmaceuticas multi-fasicas de farmacos pobremente solubles en agua para una biodisponibilidad oral de variabilidad alimentada/en ayunas reducida y mejorada. | |
| EA201490014A1 (ru) | Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот | |
| WO2006051110A3 (en) | Stable formulations of insulinoptropic peptides | |
| WO2006035417A3 (en) | Dihydropyrimidine microcapsule - formulations | |
| WO2006135933A3 (en) | Stable fixed-dose unitary formulations containing tenofovir, a surfactant, efavirenz and emtricitabine | |
| ZA200809864B (en) | Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic | |
| WO2012048854A3 (en) | Formulation suitable for stabilizing proteins, which is free of mammalian excipients | |
| AU2003270255A1 (en) | Fast releasing, solid administration form for oral application of active ingredients which are hard to dissolve | |
| ZA200900929B (en) | Microparticles based on an amphiphilic copolymer and on active ingredient(s) with modified release and pharmaceutical formulations containing same | |
| WO2009060952A1 (ja) | 新規製剤 | |
| WO2012085284A3 (en) | High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts | |
| WO2011076209A3 (en) | Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue | |
| SMT201300106B (it) | Composizioni biodisponibili di composto alfa-(N-sulfonammido)acetammide amorfo | |
| WO2012147101A3 (en) | Pharmaceutical compositions of raltegravir, methods of preparation and use thereof | |
| WO2007077318A3 (fr) | Utilisation d'un extrait peptidique de riz en tant qu'agent actif inducteur de la synthese des proteines sirt dans les cellules de la peau | |
| EA200801614A1 (ru) | Фармацевтическая композиция, содержащая монтелукаст | |
| WO2007100282A8 (en) | New salts of an indole derivative and their use in medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |